Ionis Chief Scientific Officer C. Frank Bennett, Ph.D. to receive Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research
Drs. Bennett, Cleveland and Miller are being recognized for their work advancing antisense technology for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), Huntington's disease, Alzheimer's disease and tauopathies. Their long-term collaboration has resulted in four investigational medicines entering clinical studies, including tofersen, currently under regulatory review for market authorization for the treatment of SOD1-ALS, with a Prescription Drug User Fee Act (PDUFA) action date of
"I'm humbled to be recognized by the
A founding member of Ionis,
The Rainwater Prize Program recognizes scientific progress toward new treatments for neurodegenerative diseases associated with the accumulation of tau protein in the brain and fosters scientific discovery by elevating awareness of the gaps in neurodegenerative research, bringing new researchers into the tauopathy field, and awarding scientific achievements that could lead to innovative, effective treatments.
For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision to become the leader in genetic medicine, utilizing a multi-platform approach to discover, develop and deliver life-transforming therapies.
To learn more about Ionis visit www.ionispharma.com and follow us on Twitter @ionispharma.
SPINRAZA®, tofersen and IONIS-MAPTRx/BIIB080 are licensed to Biogen. Tominersen is licensed to Roche.
Ionis' Forward-looking Statements
This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of Ionis' technologies, SPINRAZA, tofersen, tominersen, IONIS-MAPTRx /BIIB080 and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including those related to the impact COVID-19 could have on our business, and including but not limited to, those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.
Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended
In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" refers to
View original content to download multimedia:https://www.prnewswire.com/news-releases/ionis-chief-scientific-officer-c-frank-bennett-phd-to-receive-rainwater-prize-for-outstanding-innovation-in-neurodegenerative-disease-research-301731075.html
Ionis Investor Contact: 760-603-2331; Ionis Media Contact: 760-603-4679